UNSPSC 51173219: Carboxymethylcellulose/casanthranol/docusate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173219 Carboxymethylcellulose/casanthranol/docusate is a Commodity code with minimal recent state and local procurement activity tied directly to this specific pharmaceutical formulation. The recent opportunities posted under or near this code do not reflect demand for carboxymethylcellulose/casanthranol/docusate as a finished drug product; instead, they show state and local procurement of broader pharmaceutical and testing services where this laxative combination may be one line item among many. The source shows no RFPs, RFQs, IBFs, or ITBs specifically for this drug by name or NDC, and no issuing body has solicited it as a standalone commodity in the recent window.

The code shows activity across Texas state agencies and multistate cooperative purchasing vehicles, but the opportunities are generic pharmaceutical frameworks or drug-testing services rather than targeted buys of this formulation. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, where carboxymethylcellulose/casanthranol/docusate could be included; and Collin County Community Supervision and Corrections Department solicited drug-testing services in July 2026 (due July 23, 2026) focused on specimen collection and lab confirmation rather than pharmaceutical supply. Pursuit of this code requires positioning as a generic pharmaceutical manufacturer or distributor capable of meeting MMCAP's cGMP and Drug Supply Chain Security Act compliance, or engaging in state-agency formulary discussions outside formal solicitation cycles. The code itself does not signal near-term standalone demand.